On August 21, Caris Life Sciences, Inc. rose 7.89% in regular trading, trading at $24.555/share with turnover of approximately $101 million, extending its recent strong performance.

The rally continues to be driven by the company's Q2 earnings released on August 5, which showed revenue of $263.7 million, significantly beating the consensus estimate of $238.1 million by approximately 10.7%. This marks another quarter of substantial outperformance following Q1 results that saw revenue surge 79% year-over-year to $216.2 million, also exceeding expectations. Full-year revenue guidance remains at $1.0 billion to $1.02 billion. The company had previously reported a Q4 EPS of $0.28, massively beating the $-0.03 estimate, with sales of $292.9 million exceeding the $208.6 million estimate.

Supporting the fundamental momentum, Caris has expanded its product portfolio with new launches including PTEN IHC testing for prostate cancer, ChromoSeq for myeloid malignancies, and an AI tool for predicting chemotherapy resistance in ovarian cancer. The company also authorized a $100 million share buyback program and secured a comprehensive credit facility with Blue Owl Capital and Blackstone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)